Skip to main content
. 2018 Jan 24;19(2):344. doi: 10.3390/ijms19020344

Figure 6.

Figure 6

Staining for CK protein in a section of heart tissue in (a) control mice showing no CK immune-reactive cells; (b) tulathromycin-treated mice showing an increased number of CK immune-reactive cells; (c) DFS-treated mice showing abundant CK immune-reactive cells; (d) tulathromycin–DFS-treated mice showing numerous CK immune-reactive cells; (e) tulathromycin–lycopene-treated mice showing few individual CK immune-reactive cells; (f) DFS–lycopene-treated mice showing sparse CK immune-reactive cells; (g) tulathromycin–DFS–lycopene-treated mice showing sporadic CK immune-reactive cells (CK immunohistochemical staining, ×400); and (h) immunohistochemical scoring of Bax protein in the heart tissue of control and treated mice. Means carrying different superscripts (a,b,c,d) are significantly different at (p < 0.05).